The 29 references in paper A. Kolbin S., I. Vilum A., Yu. Balykina E., M. Proskurin A., А. Колбин С., И. Вилюм А., М. Проскурин А., Ю. Балыкина Е. (2015) “Фармакоэкономический анализ применения лекарственного препарата Рибомустин® в терапии первой линии множественной миеломы для пациентов старше 65 лет // PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD” / spz:neicon:pharmacoeconomics:y:2014:i:2:p:6-12

1
Abdulkadyrov K.M. clinical hematology [Klinicheskaya gematologiya]. St. Petersburg. 2006; 447 s.
(check this in PDF content)
2
Avksent'eva M.A., Gerasimov B.V., Sura M.V. Clinical and economic analysis (evaluation, selection of medical technology and quality management of medical care). Ed. Vorobyov PA [Klinikoekonomicheskii analiz (otsenka, vybor meditsinskikh tekhnologii i upravleniya kachestvom meditsinskoi pomoshchi). Pod red. Vorob'eva] P.A. Moscow. 2004; 404 s.
(check this in PDF content)
3
Andreeva N.E., Balakireva T.V. Paroproteinemicheskie gemablostozy: Multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease [Paroproteinemicheskie gemablostozy: Mnozhestvennaya mieloma, makroglobulinemiya Val'denstrema, bolezni tyazhelykh tsepei]. Tver'. 2003; 88 s.
(check this in PDF content)
4
Belousov Yu.B. Planning and conduct of clinical trials of medicinal products [Planirovanie i provedenie klinicheskikh issledovanii lekar-stvennykh sredstv]. Moscow. 2000; 579 s.
(check this in PDF content)
5
Belousov D.Yu., Afanas'eva E.V., Efremova E.A. Kachestvennaya klinicheskaya praktika. 2013; 3: 15-20.
(check this in PDF content)
6
Diagnosis and treatment of multiple myeloma. Recommendations of the British Forum for multiple myeloma and Scandinavian Study Group myeloma [Diagnostika i lechenie mnozhestvennoi mielomy. Rekomendatsii Britanskogo foruma po mnozhestvennoi mielome i Skandinavskoi issledovatel'skoi gruppy po mnozhestvennoi mielome]. 2005.
(check this in PDF content)
7
National clinical guidelines for the diagnosis and treatment set myeloma. Hematology and Blood Transfusion. Application number 3 [Natsional'nye klinicheskie rekomendatsii po diagnostike i lecheniyu mnozhe-stvennoi mielomy. Gematologiya i transfuziologiya. Prilozhenie No 3]. 2014 (1).
(check this in PDF content)
8
On approval of the industry standard «clinical research ekonomieskie. General»: the order number 163 of the Ministry of Health of the Russian Federation dated 27.05.2011.
(check this in PDF content)
9
Government Decree of October 22, 2012 No 1074 «On the program of state guarantees of free citizens providing medical care for 2013 and the planning period of 2014 and 2015».
(check this in PDF content)
10
Decree of the Government of St. Petersburg from 26.02.2010 No 176 «On the establishment of trade price premiums for drugs and medical products».
(check this in PDF content)
11
Professional pharmaceutical portal «FARMindeks» [Professional'nyi farmatsevticheskii portal «FARMindeks»]. http:// www.pharmindex.ru/.
(check this in PDF content)
12
The Order of the Ministry of Health of 24.12.2012, No 1458n «On approval of the standard of primary health care in refractory and recurrent C. for SRI multiple myeloma and other plasma cell malignant neoplasms».
(check this in PDF content)
13
Regulation of the Committee on Economic Policy and Strategic Planning of St. Petersburg of 17.07.2013 N 103-p «On approval of the financial cost of providing public services (works) for specialized medical care in geriatric institutions (offices, classrooms) care provided in hospices (offices, hospices), and medical care provided in nursing departments, autonomous and state budgetary institutions».
(check this in PDF content)
14
Rudakova A.V. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2011; 4 (3): 29-33.
(check this in PDF content)
15
Rudakova A.V. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2011; 4 (3): 23-28.
(check this in PDF content)
16
Site of the State register of medicines. http:// grls.rosminzdrav.ru.
(check this in PDF content)
17
Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J. Clin. Oncol. 2009; 27: 1492-501.
(check this in PDF content)
18
http://www.spboms.ru/kiop/main?page_id=338.
(check this in PDF content)
19
http://www.pokrov.spb.ru/stoimostq-uslug.html.
(check this in PDF content)
20
Leoni L. et al. Clin. Cancer. Res. 2008; 309 (14): 309-317.
(check this in PDF content)
21
Moreau P., Pylypenko H., Grosicki S. et al. Subcutaneous versus intravenous admin-istration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet. Oncol. 2011; 12: 431-40.
(check this in PDF content)
22
Mateos M.V., Hernandenz J.M., Hernandenz M.T. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multcenter phase 1/2 study. Blood. 2006; 108: 2165-2172. PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN®IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD Kolbin A.S.1,2, Vilum I.A.3, Balykina Yu.E.2, Proskurin M.A.2 1First Pavlov State Medical University of St. Peterburg 2Saint Petersburg State University, St. Petersburg, Russia 3 National Medical and Surgical Center of the N.I. Pirogov, St. Peterburg Abstract: we have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of bendamustine in the first line of therapy of a multiple myeloma
(check this in PDF content)
23
Palumbo A. et al. Bortezomib-Melphalan-PrednisoneThalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Im-proved Survival. Journal of Clinical Oncology. 2014 January 21. [EPub Ahead of Print].
(check this in PDF content)
24
Ponisch W. et al., Treatment of bendamustine and prednisone in patients with newly di-agnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of He-matology and Oncology (OSHO). J. Cancer. Res. Clin. Oncol. 2006. 132 (4): 205-12.
(check this in PDF content)
25
Rummel M.J., Al-Batran S., Kim S.Z. et al: Ribomustin plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 2005; 23: 3383-3389.
(check this in PDF content)
26
San Miguel J.F., Schalg R., Khuageva N. et al. MMY-3002: A phase-3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Blood. 2007; 110: 31a (abstract 76).
(check this in PDF content)
27
URL: www.medlux.ru.
(check this in PDF content)
28
Walley T., Haycox A., Boland A. Pharmacoeconomics. Elsevier Health Sciences. 2004; 216 s.
(check this in PDF content)
29
Weinstein M.C., O'Brien B., Hornberger J. et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies.Value Health. 2003; 6 (1): 9-17.
(check this in PDF content)